改良肺超声评分评估Covid-19肺炎严重程度
研究纳入44例确诊COVID-19肺炎患者,按病情严重程度分为轻/中度(I组)、重度(II组)和危重症(III组),评估改良肺超声评分(mLUS)与病情严重程度及临床参数的关系。结果显示I-III组mLUS分别为6.51±4.12、23.5±5.9和24.7±3.9,II、III组显著高于I组;mLUS与年龄和NT-proBNP呈正相关,与PaO2/FiO2呈负相关。
要点
- mLUS在重度(23.5±5.9)和危重症(24.7±3.9)患者中显著高于轻/中度(6.51±4.12)。
- mLUS与年龄、NT-proBNP呈正相关,与PaO2/FiO2呈负相关。
- COVID-19肺炎中mLUS随疾病严重程度增加而显著升高。
核心结论
- 在COVID-19肺炎患者中,mLUS随疾病严重程度增加而显著升高。
研究设计与样本
- 研究纳入44例确诊COVID-19肺炎患者,按肺炎严重程度分为轻/中度(I组)、重度(II组)和危重症(III组)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Severe acute respiratory syndrome coronavirus 2 causes coronavirus disease 2019 (Covid-19), which has been declared as a pandemic by the World Health Organization. The aim of the study described here was to determine the severity of pneumonia and the clinical parameters related to a modified lung ultrasound score (mLUS) in patients with COVID-19 pneumonia. The study included 44 patients with proven COVID-19 pneumonia. Patients were divided into three groups on the basis of pneumonia severity: mild/moderate pneumonia (group I), severe pneumonia (group II) and critically ill patients (group III). It was determined that mLUS values in groups I-III were 6.51 ± 4.12, 23.5 ± 5.9 and 24.7 ± 3.9, respectively. mLUS values were significantly higher in group II and III patients than in group I patients. There was a positive relationship between mLUS and age and N-terminal pro-brain natriuretic peptide level and a negative relationship with PaO2/FiO2 (p = 0.032, β = 0.275 vs. p = 0.012, β = 0.315 vs. p = 0.001, β = -0.520, respectively). In patients with COVID-19 pneumonia, mLUS increases significantly with the severity of the disease.
引用
- Sumbul HE, Koc AS, Pınar A, et al. Modified Lung Ultrasound Score in Evaluating the Severity of Covid-19 Pneumonia. Ultrasound Med Biol. 2021. PMID: 34088529. doi:10.1016/j.ultrasmedbio.2021.04.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。